Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam F, Ford JM, O'Dwyer PJ, Shapiro GI, McShane LM, Freidlin B, O'Cearbhaill RE, George S, Glade-Bender J, Lyman GH, Tricoli JV, Patton D, Hamilton SR, Gray RJ, Hawkins DS, Ramineni B, Flaherty KT, Grivas P, Yap TA, Berlin J, Doroshow JH, Harris LN, Moscow JA. Meric-Bernstam F, et al. Among authors: yap ta. Clin Cancer Res. 2023 Apr 14;29(8):1412-1422. doi: 10.1158/1078-0432.CCR-22-3334. Clin Cancer Res. 2023. PMID: 36662819 Free PMC article. Clinical Trial.
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Alhalabi O, et al. Among authors: yap ta. Mol Cancer Res. 2021 Mar;19(3):395-402. doi: 10.1158/1541-7786.MCR-20-0751. Epub 2020 Dec 15. Mol Cancer Res. 2021. PMID: 33323389
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. Hegde A, et al. Among authors: yap ta. Clin Cancer Res. 2021 Jun 1;27(11):3050-3060. doi: 10.1158/1078-0432.CCR-20-4118. Epub 2021 Mar 26. Clin Cancer Res. 2021. PMID: 33771853 Free PMC article. Clinical Trial.
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. Jhaveri K, et al. Among authors: yap ta. Expert Rev Anticancer Ther. 2021 Oct;21(10):1105-1124. doi: 10.1080/14737140.2021.1944109. Epub 2021 Sep 1. Expert Rev Anticancer Ther. 2021. PMID: 34176404 Review.
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Evans KW, et al. Among authors: yap ta. Cancer Res. 2021 Nov 1;81(21):5572-5581. doi: 10.1158/0008-5472.CAN-20-3242. Epub 2021 Sep 13. Cancer Res. 2021. PMID: 34518211 Free PMC article.
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.
Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H; PDXNet Consortium; Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA 2nd, Chuang JH. Koc S, et al. NAR Cancer. 2022 Apr 22;4(2):zcac014. doi: 10.1093/narcan/zcac014. eCollection 2022 Jun. NAR Cancer. 2022. PMID: 35475145 Free PMC article.
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. Yap TA, et al. Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. doi: 10.1158/1078-0432.CCR-21-4256. Clin Cancer Res. 2022. PMID: 35511938 Free PMC article.
236 results